Centene Corporation (NYSE:CNC) Director Robert K. Ditmore sold 8,750 shares of the firm’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $104.30, for a total transaction of $912,625.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Robert K. Ditmore also recently made the following trade(s):
- On Thursday, October 26th, Robert K. Ditmore sold 4,167 shares of Centene stock. The stock was sold at an average price of $90.42, for a total transaction of $376,780.14.
Shares of Centene Corporation (CNC) opened at $105.97 on Wednesday. Centene Corporation has a twelve month low of $61.03 and a twelve month high of $106.74. The firm has a market cap of $18,290.00, a PE ratio of 21.89, a P/E/G ratio of 1.32 and a beta of 0.70. The company has a current ratio of 0.99, a quick ratio of 0.99 and a debt-to-equity ratio of 0.71.
Several research firms have recently issued reports on CNC. ValuEngine upgraded shares of Centene from a “hold” rating to a “buy” rating in a report on Sunday, December 31st. Oppenheimer restated a “buy” rating and issued a $105.00 target price on shares of Centene in a report on Friday, September 29th. Goldman Sachs Group began coverage on shares of Centene in a report on Wednesday, January 3rd. They issued a “buy” rating and a $135.00 target price for the company. Leerink Swann restated a “market perform” rating and issued a $90.00 target price (up previously from $78.00) on shares of Centene in a report on Wednesday, September 13th. Finally, Cowen restated an “outperform” rating and issued a $105.00 target price (up previously from $77.00) on shares of Centene in a report on Wednesday, September 13th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Centene has an average rating of “Buy” and a consensus target price of $104.21.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Columbus Circle Investors bought a new stake in Centene during the 3rd quarter valued at about $9,387,000. Arrowstreet Capital Limited Partnership bought a new stake in Centene during the 2nd quarter valued at about $455,000. Handelsbanken Fonder AB lifted its holdings in Centene by 29.0% during the 3rd quarter. Handelsbanken Fonder AB now owns 178,000 shares of the company’s stock valued at $17,225,000 after buying an additional 40,000 shares in the last quarter. Trustmark National Bank Trust Department purchased a new position in Centene during the 3rd quarter valued at about $291,000. Finally, Allen Investment Management LLC purchased a new position in Centene during the 3rd quarter valued at about $327,000. Institutional investors own 91.84% of the company’s stock.
Centene Corporation is a healthcare company. The Company provides a portfolio of services to government sponsored healthcare programs, focusing on under-insured and uninsured individuals. The Company operates through two segments: Managed Care and Specialty Services. The Company’s Managed Care segment provides health plan coverage to individuals, through government subsidized programs, including Medicaid, the State Children’s Health Insurance Program (CHIP), Long Term Care, Foster Care, dual-eligible individuals (Duals) and the Supplemental Security Income Program, also known as the Aged, Blind or Disabled Program (ABD), Medicare, and Health Insurance Marketplace.
What are top analysts saying about Centene? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Centene and related companies.